



HAL
open science

Presence of occult HBV, but near absence of active HBV and HCV infections in people infected with HIV in rural South Africa

Roos Emilie Barth, Quirine Huijgen, Hugo A Tempelman, Tania Mudrikova, Annemarie Mj Wensing, Andy I.M. Hoepelman

► **To cite this version:**

Roos Emilie Barth, Quirine Huijgen, Hugo A Tempelman, Tania Mudrikova, Annemarie Mj Wensing, et al.. Presence of occult HBV, but near absence of active HBV and HCV infections in people infected with HIV in rural South Africa. *Journal of Medical Virology*, 2011, 83 (6), pp.929. 10.1002/jmv.22026 . hal-00633212

HAL Id: hal-00633212

<https://hal.science/hal-00633212>

Submitted on 18 Oct 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Presence of occult HBV, but near absence of active HBV and HCV infections in people infected with HIV in rural South Africa

Journal:	<i>Journal of Medical Virology</i>
Manuscript ID:	JMV-10-2037.R1
Wiley - Manuscript type:	Research Article
Date Submitted by the Author:	11-Nov-2010
Complete List of Authors:	Barth, Roos; University Medical Centre Utrecht, Internal Medicine and Infectious Diseases Huijgen, Quirine; University Medical Centre Utrecht, Faculty of Medicine Tempelman, Hugo; Ndlovu Medical Centre Mudrikova, Tania; University Medical Centre Utrecht, Internal Medicine and Infectious Diseases Wensing, Annemarie; University Medical Centre Utrecht, Virology and Microbiology Hoepelman, Andy; University Medical Centre Utrecht, Internal Medicine and Infectious Diseases
Keywords:	hepatitis B, hepatitis C, occult infection, Sub-Saharan Africa, Human immunodeficiency syndrome

SCHOLARONE™
Manuscripts

JMV-10-2037

1
2
3
4 1
5
6 2 **Presence of occult HBV, but near absence of active HBV and HCV**
7
8
9 3 **infections in people infected with HIV in rural South Africa**
10
11
12 4

13
14
15 5 **Running head:** Occult hepatitis in rural South Africa
16
17 6

18
19
20 7 Roos E Barth^{*1}, Quirine Huijgen², Hugo A Tempelman³, Tania Mudrikova¹, Annemarie MJ
21
22 8 Wensing⁴, Andy IM Hoepelman¹
23
24 9

25
26
27 10 ¹: University Medical Centre Utrecht, Department of Internal Medicine and
28
29 11 Infectious Diseases. Utrecht, the Netherlands
30
31

32 12 ²: Medical student at the University Medical Centre Utrecht. Utrecht, the
33
34 13 Netherlands
35
36

37 14 ³: Ndlovu Medical Centre, Elandsdoorn, Limpopo, South Africa
38
39

40 15 ⁴: University Medical Centre Utrecht, Department of Virology and Microbiology.
41
42 16 Utrecht, the Netherlands
43
44

45 17
46
47 18 This work was performed both at the Ndlovu Medical Centre in South Africa and at the
48
49 19 University Medical Centre Utrecht in the Netherlands
50
51

52
53 20
54
55 21 **Correspondence to*:**

56
57 22 Roos E Barth
58
59
60

1
2
3 1 University Medical Centre Utrecht
4

5
6 2 F02.126
7

8 3 Postbus 85500
9

10 4 3508 GA Utrecht
11

12 5 The Netherlands
13

14 6 E-mail: r.e.barth@University Medical Centre Utrechtrecht.nl
15

16 7 Tel no: 0031-621224407
17

18 8 Fax no: 0031-302523741
19

20 9
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Abstract:**
4

5
6 Human immunodeficiency (HIV), hepatitis B (HBV) and hepatitis C (HCV) viruses are
7
8 endemic in Sub-Saharan Africa, but data regarding the prevalence of hepatitis co-
9
10 infections in HIV-positive individuals residing there are limited. The aim of the study was
11
12 to determine the prevalence of HBV, HCV and occult HBV (presence of HBV-DNA in the
13
14 absence of HBsAg) in a rural, South African cohort. The results were compared to
15
16 various ethnic groups in a Dutch cohort of people infected with HIV. Antiretroviral-naïve
17
18 individuals with HIV from both a rural South African clinic (n=258), and a Dutch
19
20 University hospital (n=782), were included. Both serological (HBV and HCV) and
21
22 molecular (occult HBV) assays were performed. Logistic regression analysis was used to
23
24 define independent predictors of a hepatitis co-infection.
25
26
27
28
29
30

31
32 HBV and HCV prevalence rates in the South African cohort were exceptionally low (0.4%,
33
34 1/242 and 0.8%, 2/242 respectively), compared to those observed in Caucasians (HBV
35
36 4.4%, HCV 10.9%) and African immigrants (HBV 8.9%, HCV 4.8%). Conversely, occult HBV
37
38 was observed in a considerable proportion (10%, 6/60) of South African patients who
39
40 were anti-HBc-positive but HBsAg-negative. Occult infections were less frequent in
41
42 Caucasians and Africans in the Dutch cohort (3.2% and 1.4% respectively). Independent
43
44 predictors for occult HBV were not identified, but a trend towards more occult HBV at
45
46 lower CD4 counts was observed.
47
48
49

50
51 Local HBV/HCV prevalence data are needed to optimise vaccination and antiretroviral
52
53 treatment strategies. Occult HBV in patients with HIV may be missed regularly when
54
55 molecular analyses are not available.
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Keywords:**

2 Hepatitis B

3 Hepatitis C

4 Human immunodeficiency virus

5 Occult infection

6 HBV-DNA

7 Sub-Saharan Africa

For Peer Review

1
2
3 **1 Introduction:**
4

5
6 2 Millions of people are infected with human immunodeficiency virus (HIV), hepatitis B
7
8 3 virus (HBV) and hepatitis C virus (HCV) globally. Sub-Saharan Africa is affected severely
9
10 4 by all three viruses; two-third of the world's 33 million people infected with HIV reside
11
12 5 there, as well as an estimated 50 million chronic HBV carriers [Modi and Feld, 2007;
13
14 6 WHO, 2002; WHO, 2007]. In addition, three percent of the African population is thought
15
16 7 to be infected with HCV [Madhava et al., 2002].
17
18

19
20 8 Chronic hepatitis can lead to cirrhosis and hepatocellular carcinoma. Due to shared
21
22 9 routes of transmission, the prevalence of HBV and HCV is believed to be high amongst
23
24 10 persons infected with HIV [Burnett et al., 2005; Thomson and Main, 2008]. Life
25
26 11 expectancy of people living with HIV in Sub-Saharan Africa has improved dramatically
27
28 12 since the increased availability of antiretroviral treatment (ART). The long-term effects
29
30 13 of HBV and HCV co-infections will therefore become more evident, causing a potential
31
32 14 increase in morbidity and mortality [Hoffmann and Thio, 2007; Modi and Feld, 2007].
33
34 15 This is stressed by the observation that the progression of HBV- and HCV-related liver
35
36 16 disease is more rapid in patients with HIV [Chen et al., 2009; Nikolopoulos et al., 2009].
37
38

39
40 17 Prior to starting ART, it is important to know whether a co-infection with hepatitis is
41
42 18 present. An increased hepatotoxicity of antiretrovirals (ARVs) and other drugs is
43
44 19 observed in patients with both HIV and hepatitis, compared to those with HIV infection
45
46 20 alone [den Brinker et al., 2000; Hoffmann et al., 2007; Sulkowski et al., 2002]. Although
47
48 21 immune reconstitution soon after initiating ART may cause further liver damage, ART
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 1 may be beneficial for patients who are co-infected with HIV and HBV, as it can be used
4
5
6 2 to treat both infections simultaneously.
7

8
9 3
10
11 4 Screening for co-infection with HBV or HCV in people infected with HIV is incorporated
12
13 5 in western clinical guidelines [BHIVA, 2010; EACS, 2009; Soriano et al., 2008; Soriano et
14
15
16 6 al., 2007]. However, consequent serological screening for hepatitis is generally not
17
18 7 feasible in low-income countries (LICs). As a result, limited HBV and HCV prevalence
19
20
21 8 data are available regarding African patients infected with HIV, and the data that are
22
23 9 available indicate wide geographical variation [Cooper et al., 2009; Hoffmann and Thio,
24
25
26 10 2007; Marcellin, 2009].
27

28
29 11 While some people have an active, HBV surface antigen (HBsAg) positive infection,
30
31 12 others may harbour an occult HBV infection. Occult hepatitis B is defined by the
32
33 13 presence of plasma HBV-DNA in individuals who are HBsAg negative. Even if serological
34
35 14 testing for HBV is available, such infections will be missed.
36
37

38
39 15
40
41 16 The aim of the current study is to assess active HBV, occult HBV and HCV prevalence
42
43 17 rates in a cohort of people infected with HIV in rural South Africa. The results were
44
45
46 18 compared to co-infection rates with HBV and HCV among Caucasian and African
47
48 19 individuals with HIV in the Netherlands. Furthermore, predictors for the presence of
49
50 20 these hepatitis viruses were determined.
51
52
53
54
55
56
57
58
59
60

1
2
3 **1 Methods:**

4
5
6 **2 *Setting and study population***

7
8 Ndlovu Medical Centre is a non-governmental organisation in Elandsdoorn
9 (www.ndlovucaregroup.com). Elandsdoorn is situated in a rural area in Limpopo, a
10 province in the north east of the Republic of South Africa. The centre provides primary
11 health care, including an ART program for people with HIV that has been active since
12 2003. Cohort details have been described elsewhere [Barth et al., 2008]. For this study,
13 all ART-naïve adults (≥ 15 years) with HIV who enrolled in the Ndlovu ART program from
14 September till November 2008, were included in this study.
15

16
17 The University Medical Centre Utrecht is an academic hospital in the city of Utrecht,
18 situated in the centre of the Netherlands. All adults (≥ 18 years) with HIV, who came into
19 care at the University Medical Centre Utrecht from January 1985 till January 2008, were
20 included. Patients were ART-naïve at time of serological HBV and HCV testing.
21

22
23 For comparisons, analyses were limited to African and Caucasian people. Asians and
24 people originating from the Americas who were in care at the University Medical Centre
25 Utrecht were excluded.
26
27

28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 **18 *Data collection and definitions***

47
48 Patient characteristics were extracted from medical charts and clinical databases. Data
49 included in the study were the following: age, gender, ethnicity, country of birth,
50 probable route of HIV transmission and baseline laboratory variables (CD4+ T-cell count,
51 ASAT, ALAT). Venous blood was collected from all patients, and standard methods for
52
53
54
55
56
57
58
59
60

1 blood sample processing were used. Plasma was locally stored at -80° C and shipped to
2 the Netherlands on dry ice.

3 HBV and HCV analyses were performed at the accredited (according to Dutch guidelines)
4 diagnostic laboratory of the virology department at the University Medical Centre
5 Utrecht. Serological tests for HBV (anti-HBc, HBsAg and anti-HBs) and HCV (anti-HCV)
6 were performed using the AxSYM[®] automated analyzer (Abbott Laboratories, Abbott
7 Park, IL, USA). Anti-HBc was determined using the COREtm[®] kit (Abbott Laboratories,
8 Abbott Park, IL, USA). Anti-HBc was considered positive if the ratio was above 1. All anti-
9 HBc-positive blood samples were tested for HBsAg and anti-HBs using HBsAg(V2) and
10 AUSAB[®] kits (Abbott Laboratories, Abbott Park, IL, USA). Ratios above 4 and 2 were used
11 to define positive anti-HBs and positive HBsAg respectively. In the case of an
12 indeterminate HBsAg result (ratio between 2 and 5) samples were centrifuged using an
13 Eppendorf centrifuge and retested.

14 HBV-DNA load was assessed in samples that tested anti-HBc positive, but did not have
15 detectable HBsAg levels. Quantitative HBV-DNA was determined using the Taqman[®] fast
16 real-time nested PCR, as described previously [Cohen Stuart et al., 2009; Pas et al.,
17 2000]. HBV-DNA was isolated using an automated nucleic acid extraction system
18 (MagNA Pure LC[®]; Roche Diagnostics, Penzberg, Germany). Lower limit of quantification
19 is 200 IU/mL; lower limit of detection is 10 IU/mL. Amplification was performed in
20 duplicate and a three-tiered control was executed (internal, no template and whole
21 procedure control). Outcomes were averaged and in the case of a 3-point difference in

1 cycle threshold values (Ct values) or a positive/negative difference, the procedures were repeated.

A positive HBsAg result was used to define an HBV infection. Patients with detectable HBV-DNA levels were considered to have HBV viremia. Patients with detectable HBV-DNA levels with the absence of HBV surface antigens were considered to have occult HBV infections.

The HCV version 3.0 kit[®] (Abbott Laboratories, Abbott Park, IL, USA) was used to determine the presence of anti-HCV. A ratio above 5 was considered positive. Blood samples with indeterminate results (ratio between 1 and 5), were centrifuged and retested. Subsequently, a western blot was performed on all blood samples with a ratio above 1, using the Autoblot 3000[®] (Innogenetics NV, Gent, Belgium). A positive western blot in anti-HCV positive individuals was used to define an HCV infection.

Statistical analysis:

Frequencies were compared using the χ^2 and Fischer's exact tests. Continuous data were compared with the independent-sample t-test or Mann Whitney U test for non-parametric data. Determinants that were associated with the outcome in univariate analysis (defined as a p-value <0.1) were included in multivariate analysis. Subsequently, logistic regression analysis was done to determine independent predictors of the outcome. A P-value $\leq 0,05$ was used to define statistical significance. Data were processed and statistical analyses were done using SPSS version 15.

1
2
3 **1 Results:**
4

5
6 **2 Patient characteristics:**
7

8
9 3 Two hundred forty-eight ART naïve adults with HIV from Elandsdoorn, South Africa were
10
11 4 included in this study. The majority of included patients were female (73.8%). The Dutch
12
13 5 cohort consisted of 846 people infected with HIV. Caucasian Europeans (614, 73%) and
14
15 6 African immigrants (168, 20%) predominated. In contrast to the South African cohort,
16
17 7 more males were included in the Dutch cohort; 535 (87%) of Caucasians and 93 (55%) of
18
19 8 African immigrants were male. Heterosexual contact was the main route of HIV
20
21 9 transmission in African immigrants and was assumed to be the HIV-transmission route in
22
23 10 all South African residents. With Caucasian Europeans, HIV was transmitted frequently
24
25 11 via homosexual contact. Baseline characteristics are summarised in Table 1.
26
27
28
29
30
31
32

33 **13 Serological evidence of HBV and HCV co-infections:**
34
35

36 14 Anti-HBc test results were available for 98% (242/248) of South African residents. Of the
37
38 15 242 patients, 68 (28.1 %) tested positive. Most anti-HBc positive patients were anti-HBs
39
40 16 positive as well (62.7%). Only one individual tested HBV surface-antigen positive. This
41
42 17 patient did not have anti-HBs. Overall, the prevalence of active HBV was only 0.4%
43
44 18 (1/242). Serological evidence of an HBV infection was predominantly present in men;
45
46 19 HBsAg and anti-HBc prevalence rates were 5.4% and 45.9% in men, compared to 2.3%
47
48 20 and 34.1% in women (p=0.2 and p<0.01 respectively). No gender difference was seen
49
50 21 with regard to the anti-HBs prevalence.
51
52
53
54
55
56
57
58
59
60

1
2
3 1 Compared to the South African cohort, anti-HBc prevalence rates were significantly
4
5
6 2 higher in both Caucasians and African immigrants (41.4% and 57.6% respectively,
7
8
9 3 $p < 0.01$). Furthermore, a larger proportion of patients was HBsAg-positive, resulting in an
10
11 4 active HBV prevalence of 4.4% in Caucasians and 8.9% in African immigrants ($p < 0.01$).
12
13
14 5 The prevalence of active HBV remained significantly lower in the South African cohort,
15
16 6 as compared to the other groups, when patients infected via heterosexual contact only
17
18
19 7 were included.
20

21 8
22
23 9 Serological evidence of an HCV infection was also infrequent in the South African cohort.
24
25
26 10 The anti-HCV prevalence rate was 0.8% for African residents, compared to 10.9% and
27
28
29 11 4.8% for Caucasians and African immigrants respectively ($p < 0.01$).
30
31 12 All serological outcome data are presented in Table 2.
32

33 13

34
35
36 14 ***Occult HBV infections:***

37
38 15 The presence of HBV-DNA was assessed in 93% (62/67) of South African patients who
39
40
41 16 were anti-HBc positive but tested HBsAg negative. For the remaining 5 individuals, an
42
43
44 17 insufficient amount of plasma was stored to perform molecular analyses. An occult HBV
45
46
47 18 infection was established in 9.7% (6/62) of tested individuals. HBV-DNA levels were low
48
49
50 19 in patients with an occult HBV infection. In 3 patients, viral loads were below the level of
51
52 20 quantification (between 10 and 200 IU/mL), twice just above this threshold (224 and
53
54 21 259 IU/mL respectively), and only once clearly higher (5222 IU/mL).
55
56
57
58
59
60

1 For 259 Dutch patients who were anti-HBc positive and HBsAg negative, HBV-DNA levels
2 were also determined. Occult HBV was present in 2.7% (7/259) of these patients. The
3 prevalence rate was higher in Caucasians (6/187, 3.2%) compared to African immigrants
4 (1/72, 1.4%), but significantly lower compared to the South African cohort ($p=0.04$).
5 Nearly half of the patients with occult HBV also had anti-HBs (6/13, 46%).
6

7 ***Predictors for co-infections with HBV or HCV:***

8 Age, gender, ethnic origin, HIV transmission route, baseline log HIV-RNA and baseline
9 CD4+ T-cell count were tested as possible determinants for having a HBV or HCV co-
10 infection. In univariate analysis, all but the CD4+ T cell count were associated with the
11 presence of HBsAg and with the presence of anti-HCV. In multivariate analysis, only
12 lower age and male gender were independently predictive of an HBV infection. The
13 determinants that remained associated with a positive anti-HCV test were Caucasian
14 ethnicity, HIV transmission route (IVDU or blood products) and a lower baseline log HIV-
15 RNA.

16 Among anti-HBc positive individuals, the above mentioned determinants and the
17 presence of anti-HCV and anti-HBs were tested as possible predictors for an occult HBV
18 infection. None remained associated significantly with this outcome in the multivariate
19 analysis, but a trend towards a higher occult HBV prevalence in case of a lower baseline
20 CD4+ T-cell count was observed (Table 3).

1
2
3 **1 Discussion:**
4

5
6 2 In this study an exceptionally low prevalence of HBs antigenemia (0.4%) and HCV
7
8 3 antibodies (0.8%) was found in a rural South African cohort of people infected with HIV.
9
10 4 Occult HBV on the other hand was observed in a considerable proportion (10%) of
11
12 5 patients who tested anti-HBc-positive and HBsAg-negative.
13
14
15
16
17

18 7 In Western countries, HBV is clearly more prevalent in people with HIV compared to
19
20 8 people without HIV [Burnett et al., 2005; Kellerman et al., 2003; Thio, 2009]. This
21
22 9 relationship is attributed to common routes of transmission. In Sub-Saharan Africa the
23
24 10 association between HBV and HIV infections is less apparent, as people generally come
25
26 11 into contact with HBV long before the acquisition of HIV. Without making a distinction
27
28 12 between people with and without HIV, HBsAg prevalence in Africa is reported to be well
29
30 13 over 8% [Barth RE, 2010; Burnett et al., 2005; CDC, 2006; WHO, 2002]. A similar rate was
31
32 14 observed among African immigrants in the current study. Published HBsAg prevalence
33
34 15 data among South African patients infected with HIV vary (5-23%, [Burnett et al., 2007;
35
36 16 Firnhaber et al., 2009; Hoffmann et al., 2008; Lukhwareni et al., 2009; Mphahlele et al.,
37
38 17 2006]), but all are well above that observed in the cohort presented here. This is
39
40 18 remarkable, as HBV prevalence rates are generally assumed to be high in rural African
41
42 19 areas [Abdool Karim et al., 1989; Kew, 1996]. It is unclear why the observed HBV
43
44 20 prevalence in this cohort is so low. Contact with high-endemic areas was possibly limited
45
46 21 due to geographical and ethnic factors that may have reduced the amount of migration
47
48 22 and number of interracial marriages.
49
50
51
52
53
54
55
56
57
58
59
60

1 The paradigm is that the vast majority of people in Sub-Saharan Africa come into
2 contact with HBV early in life. This would result in the presence of anti-HBc in 70-95% of
3 individuals [Burnett et al., 2005; Modi and Feld, 2007]. However, the majority (73%) of
4 patients infected with HIV in this South African cohort lacked anti-HBc. These results are
5 in line with other studies in South Africa that reported rather low anti-HBc prevalence
6 rates (35-38%, [Burnett et al., 2007; Firnhaber et al., 2009; Lukhwareni et al., 2009]).
7 People without anti-HBc are still at risk for acquiring HBV. Therefore, providing them
8 with an HBV vaccine may be worth considering. Such vaccination is common practice in
9 western countries. Future studies will have to establish the risk of acquiring HBV at an
10 older age in African settings and determine whether routine vaccination of patients with
11 HIV who test anti-HBc negative is cost-effective there.

12 Reported anti-HCV prevalence rates for peoples infected with HIV in Africa vary; for
13 South Africa 1 to 13% of people with HIV are believed to be co-infected with HCV
14 [Lodenyo et al., 2000; Mphahlele et al., 2006; Parboosing et al., 2008]. In LICs, the
15 clinical consequences of being infected with HCV are limited. Treating HCV is generally
16 not feasible due to high costs and frequent adverse events associated with currently
17 available therapies. Moreover, a HCV vaccine is not yet available.

18 Although active HBV was detected rarely in the current study, a considerable proportion
19 of anti-HBc positive patients in South Africa harboured an occult HBV co-infection.
20 Previous South African studies reported approximately 23% of people with HIV - who
21 tested anti-HBc positive and HBsAg negative - to have detectable HBV-DNA levels
22 [Lukhwareni et al., 2009; Mphahlele et al., 2006]. In one study that included severely

1 immunocompromised patients infected with HIV (mean CD4+ t-cell count 49 cells/mm³),
2 an even higher rate of occult HBV (88%) was found [Firnhaber et al., 2009]. These
3 observations contribute to the idea that occult HBV represents opportunistic viral
4 reactivation [Cohen Stuart et al., 2009; Lo Re et al., 2007; Shire et al., 2007]. In the
5 current study, a significant association between the level of immunosuppression and the
6 presence of occult HBV was not found, but a trend towards more occult infections in the
7 case of a lower CD4 count was observed. In accordance with other African cohorts
8 [Harania et al., 2008; Nagu et al., 2008], no correlation between the CD4+ T-cell count
9 and the presence of an active HBV or HCV infection was found. The idea that HCV-
10 infected individuals show the highest occult HBV prevalence [Raimondo et al., 2007]
11 could not be confirmed by the data presented here.

12 In patients having an occult HBV infection only, occult HBV is linked to the transmission
13 of HBV and the development of liver disease [Raimondo et al., 2007]. However, in the
14 absence of prospective studies, it is unclear whether occult infections are associated
15 with higher liver-related morbidity and mortality rates. Moreover, the clinical relevance
16 of occult HBV is debatable as HBV-DNA loads are generally low and are likely to become
17 undetectable with lamivudine, the only drug with anti-HBV activity included frequently
18 in African ART regimens [Cohen Stuart et al., 2009].

19
20 There are potential limitations to this study. First, molecular analyses were limited to
21 anti-HBc positive individuals. Although an occult HBV infection is associated with the
22 presence of anti-HBV antibodies, a minority of occult carriers are negative for all HBV

1 serum markers [Torbenson and Thomas, 2002]. Such cases would not have been
2 identified. Second, due to the low HBV-DNA levels (all but one <1000 copies/mL) and
3 the limited amount of plasma available, in-depth virological characterisation of HBV-
4 DNA positive specimens was not performed. The possibility of a false positive result can
5 therefore not be ruled out completely, but is unlikely considering the extensive control
6 procedure that was applied. Third, the cohorts under study vary with regard to gender
7 distribution, nadir CD4 counts and routes of transmission. This may have contributed to
8 the observed difference in co-infection rates. Nonetheless, the results remain of interest
9 as the differences in baseline characteristics represent how the epidemics vary between
10 different geographical areas.

11
12 In conclusion, an exceptionally low frequency of HBV and HCV was observed in a cohort
13 of individuals infected with HIV in rural South Africa. Rates were lower compared to
14 both Caucasians and African immigrants who are receiving care in the Netherlands.
15 Occult HBV on the other hand was observed more often in the South African cohort.
16 This study highlights the need for local HBV/HCV prevalence data in order to guide
17 decisions on future vaccination and treatment strategies.

18
19 **Conflicts of Interest:**

20 The authors have no conflicts of interest to declare.

21 **Ethics Statement:**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 This study was performed in compliance with relevant laws and institutional guidelines
2 and in accordance with the ethical standards of the Declaration of Helsinki.
3 Due to the retrospective nature of this study, no experiments were performed; only
4 data used for clinical practice were included.

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
References:

- 2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Abdool Karim SS, Thejpal R, Singh B. 1989. High prevalence of hepatitis B virus infection in rural black adults in Mseleni, South Africa. *Am J Public Health* 79(7):893-894.
- Barth RE, van der Meer JT, Hoepelman AI, Schrooders PA, van de Vijver DA, Geelen SP, Tempelman HA. 2008. Effectiveness of highly active antiretroviral therapy administered by general practitioners in rural South Africa. *Eur J Clin Microbiol Infect Dis* 27(10):977-984.
- Barth RE, Huigen Q, Taljaard J, Hoepelman AIM. 2010. Hepatitis B/C and HIV in Sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. *International Journal of Infectious Diseases*: accepted for publication.
- British HIV Association. 2010. Guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus. Available at: http://www.bhiva.org/documents/Guidelines/HepBC/2010/hiv_2781.pdf.
- Burnett RJ, Francois G, Kew MC, Leroux-Roels G, Meheus A, Hoosen AA, Mphahlele MJ. 2005. Hepatitis B virus and human immunodeficiency virus co-infection in sub-Saharan Africa: a call for further investigation. *Liver Int* 25(2):201-213.
- Burnett RJ, Ngobeni JM, Francois G, Hoosen AA, Leroux-Roels G, Meheus A, Mphahlele MJ. 2007. Increased exposure to hepatitis B virus infection in HIV-positive South African antenatal women. *Int J STD AIDS* 18(3):152-156.
- CDC. 2006. Prevalence of chronic infection with hepatitis B virus. Available at: <http://wwwnc.cdc.gov/travel/yellowbook/2010/chapter-2012/hepatitis-b.aspx>.
- Chen TY, Ding EL, Seage Iii GR, Kim AY. 2009. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. *Clin Infect Dis* 49(10):1605-1615.
- Cohen Stuart JW, Velema M, Schuurman R, Boucher CA, Hoepelman AI. 2009. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. *J Med Virol* 81(3):441-445.
- Cooper CL, Mills E, Wabwire BO, Ford N, Olupot-Olupot P. 2009. Chronic viral hepatitis may diminish the gains of HIV antiretroviral therapy in sub-Saharan Africa. *Int J Infect Dis* 13(3):302-306.
- den Brinker M, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van Leeuwen R, Pakker NG, Reiss P, Danner SA, Weverling GJ, Lange JM. 2000. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. *Aids* 14(18):2895-2902.
- EACS. 2009. Guidelines clinical management and treatment of chronic hepatitis B and C co-infection in HIV-infected adults. Available at: http://www.europeanclinicalinfectiousdisease.org/guidelinespdf/3_Chronic_Hepatitis_B_&_C.pdf.
- Firnhaber C, Viana R, Reyneke A, Schultze D, Malope B, Maskew M, Di Bisceglie A, MacPhail P, Sanne I, Kew M. 2009. Occult hepatitis B virus infection in patients

- 1 with isolated core antibody and HIV co-infection in an urban clinic in
2 Johannesburg, South Africa. *Int J Infect Dis* 13(4):488-492.
- 3 Harania RS, Karuru J, Nelson M, Stebbing J. 2008. HIV, hepatitis B and hepatitis C
4 coinfection in Kenya. *Aids* 22(10):1221-1222.
- 5 Hoffmann CJ, Thio CL. 2007. Clinical implications of HIV and hepatitis B co-infection in
6 Asia and Africa. *Lancet Infect Dis* 7(6):402-409.
- 7 Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, Fielding KL, Churchyard GJ,
8 Chaisson RE, Grant AD. 2007. Hepatotoxicity in an African antiretroviral therapy
9 cohort: the effect of tuberculosis and hepatitis B. *Aids* 21(10):1301-1308.
- 10 Hoffmann CJ, Charalambous S, Martin DJ, Innes C, Churchyard GJ, Chaisson RE, Grant
11 AD, Fielding KL, Thio CL. 2008. Hepatitis B virus infection and response to
12 antiretroviral therapy (ART) in a South African ART program. *Clin Infect Dis*
13 47(11):1479-1485.
- 14 Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. 2003. Prevalence of chronic
15 hepatitis B and incidence of acute hepatitis B infection in human
16 immunodeficiency virus-infected subjects. *J Infect Dis* 188(4):571-577.
- 17 Kew MC. 1996. Progress towards the comprehensive control of hepatitis B in Africa: a
18 view from South Africa. *Gut* 38 Suppl 2:S31-36.
- 19 Lo Re V, 3rd, Frank I, Gross R, Dockter J, Linnen JM, Giachetti C, Tebas P, Stern J,
20 Synnestvedt M, Localio AR, Kostman JR, Strom BL. 2007. Prevalence, risk factors,
21 and outcomes for occult hepatitis B virus infection among HIV-infected patients.
22 *J Acquir Immune Defic Syndr* 44(3):315-320.
- 23 Lodenyo H, Schoub B, Ally R, Kairu S, Segal I. 2000. Hepatitis B and C virus infections and
24 liver function in AIDS patients at Chris Hani Baragwanath Hospital, Johannesburg.
25 *East Afr Med J* 77(1):13-15.
- 26 Lukhwareni A, Burnett RJ, Selabe SG, Mzileni MO, Mphahlele MJ. 2009. Increased
27 detection of HBV DNA in HBsAg-positive and HBsAg-negative South African
28 HIV/AIDS patients enrolling for highly active antiretroviral therapy at a Tertiary
29 Hospital. *J Med Virol* 81(3):406-412.
- 30 Madhava V, Burgess C, Drucker E. 2002. Epidemiology of chronic hepatitis C virus
31 infection in sub-Saharan Africa. *Lancet Infect Dis* 2(5):293-302.
- 32 Marcellin P. 2009. Hepatitis B and hepatitis C in 2009. *Liver Int* 29 Suppl 1:1-8.
- 33 Modi AA, Feld JJ. 2007. Viral hepatitis and HIV in Africa. *AIDS Rev* 9(1):25-39.
- 34 Mphahlele MJ, Lukhwareni A, Burnett RJ, Moropeng LM, Ngobeni JM. 2006. High risk of
35 occult hepatitis B virus infection in HIV-positive patients from South Africa. *J Clin*
36 *Virol* 35(1):14-20.
- 37 Nagu TJ, Bakari M, Matee M. 2008. Hepatitis A, B and C viral co-infections among HIV-
38 infected adults presenting for care and treatment at Muhimbili National Hospital
39 in Dar es Salaam, Tanzania. *BMC Public Health* 8:416.
- 40 Nikolopoulos GK, Paraskevis D, Hatzitheodorou E, Moschidis Z, Sypsa V, Zavitsanos X,
41 Kalapothaki V, Hatzakis A. 2009. Impact of hepatitis B virus infection on the
42 progression of AIDS and mortality in HIV-infected individuals: a cohort study and
43 meta-analysis. *Clin Infect Dis* 48(12):1763-1771.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 1 Parboosing R, Paruk I, Laloo UG. 2008. Hepatitis C virus seropositivity in a South African
2 Cohort of HIV co-infected, ARV naive patients is associated with renal
3 insufficiency and increased mortality. *J Med Virol* 80(9):1530-1536.
- 4 Pas SD, Fries E, De Man RA, Osterhaus AD, Niesters HG. 2000. Development of a
5 quantitative real-time detection assay for hepatitis B virus DNA and comparison
6 with two commercial assays. *J Clin Microbiol* 38(8):2897-2901.
- 7 Raimondo G, Pollicino T, Cacciola I, Squadrito G. 2007. Occult hepatitis B virus infection.
8 *J Hepatol* 46(1):160-170.
- 9 Shire NJ, Rouster SD, Stanford SD, Blackard JT, Martin CM, Fichtenbaum CJ, Sherman KE.
10 2007. The prevalence and significance of occult hepatitis B virus in a prospective
11 cohort of HIV-infected patients. *J Acquir Immune Defic Syndr* 44(3):309-314.
- 12 Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M, Mauss S, Brau N,
13 Hatzakis A, Pol S, Rockstroh J. 2007. Care of patients coinfecting with HIV and
14 hepatitis C virus: 2007 updated recommendations from the HCV-HIV
15 International Panel. *Aids* 21(9):1073-1089.
- 16 Soriano V, Puoti M, Peters M, Benhamou Y, Sulkowski M, Zoulim F, Mauss S, Rockstroh J.
17 2008. Care of HIV patients with chronic hepatitis B: updated recommendations
18 from the HIV-Hepatitis B Virus International Panel. *Aids* 22(12):1399-1410.
- 19 Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. 2002. Hepatotoxicity
20 associated with nevirapine or efavirenz-containing antiretroviral therapy: role of
21 hepatitis C and B infections. *Hepatology* 35(1):182-189.
- 22 Thio CL. 2009. Hepatitis B and human immunodeficiency virus coinfection. *Hepatology*
23 49(5 Suppl):S138-145.
- 24 Thomson EC, Main J. 2008. Epidemiology of hepatitis C virus infection in HIV-infected
25 individuals. *J Viral Hepat* 15(11):773-781.
- 26 Torbenson M, Thomas DL. 2002. Occult hepatitis B. *Lancet Infect Dis* 2(8):479-486.
- 27 WHO. 2002. Hepatitis B. Department of communicable diseases surveillance and
28 response. Accessed at:
29 [http://www.who.int/csr/disease/hepatitis/HepatitisB_whocdscrlyo2002_2002.](http://www.who.int/csr/disease/hepatitis/HepatitisB_whocdscrlyo2002_2002.pdf)
30 [pdf.](http://www.who.int/csr/disease/hepatitis/HepatitisB_whocdscrlyo2002_2002.pdf)
- 31 WHO. 2007. Sub-Saharan Africa. AIDS epidemic update Regional Summary. Accessed at:
32 [http://data.unaids.org/pub/Report/2008/JC1526_epibriefs_subsaharanafrika_en](http://data.unaids.org/pub/Report/2008/JC1526_epibriefs_subsaharanafrika_en.pdf)
33 [.pdf.](http://data.unaids.org/pub/Report/2008/JC1526_epibriefs_subsaharanafrika_en.pdf)
34
35

Table 1: Baseline characteristics of the different cohorts of persons who were infected with HIV, but antiretroviral naïve

	Caucasians ^a (n=614)	African immigrants (n=168)	Asian immigrants ^b (n=34)	South American immigrants ^b (n=30)	South African residents (n=248)
Age, years; mean (SD)	40,1 (10,4)	31,8 (8,6)	34,0 (7,9)	34,7 (8,2)	40,5 (9,4)
Female gender; n (%)	79 (13)	93 (55)	12 (35)	8 (27)	158 (74)
HIV-transmission route; n (%)					
• Heterosexual	180 (29)	156 (93)	25 (74)	17 (57)	250 (100) ^c
• Homosexual	371 (60)	4 (2)	9 (26)	13 (43)	-
• Blood products	20 (3)	2 (1)	-	-	-
• IV drug use	26 (4)	1 (1)	-	-	-
• Unknown	17 (3)	5 (3)	-	-	-
CD4, cells/mm ³ ; median (IQR)	337 (159-549)	264 (155-420)	232 (137-503)	378 (115-625)	273 (91-393)
ASAT, U/l; median (IQR)	31 (24-43)	35 (27-50)	33 (24-43)	36 (28-49)	32 (20-52) ^d
ALAT, U/l; median (IQR)	27 (20-44)	22 (16-35)	31 (17-47)	26 (18-45)	24 (17-37) ^d

^a: Mainly western Europeans. This group also includes 12 Eastern Europeans, 3 patients from the USA and 1 from Australia. ^b: Asian and South American immigrants were excluded from further analyses. ^c: HIV-transmission route was not clearly documented in Elandsdoorn, South Africa. Heterosexual contact was considered to be the most probable route of transmission. ^d: ASAT and ALAT in Elandsdoorn were only tested when patients started ART. Results are therefore based on a mere subset of patients.

n: number of patients, SD: standard deviation, %: percentage of patients, IV drug use: intravenous drug use, CD4: number of CD4+ T-cells, IQR: inter-quartile range

Table 2: Serological outcome data according to ethnicity

	Caucasians (n=607)	African immigrants (n=168)	South African residents (n=242)
HBsAg, n (%)	27 (4.4)	15 (8.9)	1 (0.4)
Anti-HBc, n (%)	251 (41.4)	97 (57.7)	68 (28.1)
• <i>also anti-HBs positive, n (%)</i> ^a	173/230 (75.2)	47/83 (56.6)	37/59 (62.7)
Anti-HCV, n (%)	66 (10.9)	8 (4.8)	2 (0.8)

n: number of patients with a positive test result, ^a: proportion of patients who were anti-HBc positive and were tested for anti-HBs

For Peer Review

Table 3:
Predictors of an occult HBV infection in anti-HBc positive individuals

	Occult HBV Yes	Occult HBV No	Univariate P value	Multivariate P value
CD4 (mean, cells/mm ³)	214	363	0.06	0.06
Presence of anti-HCV (%)	7.1	11.8	0.94	-
Presence of anti-HBs (%)	63.6	67.9	0.77	-
10log HIV-RNA (mean)	5.0	4.5	0.25	-
Ethnic origin (%)			0.02	0.18
• Caucasians	46.2	59.1		
• African immigrants	7.7	24.4		
• South Africans	46.2	16.5		
Male gender (%)	64.3	72.4	0.51	-
HIV transmission route (%)			0.70	-
• Heterosexual	57.1	48.3		
• Homosexual	35.7	46.1		
• IV drug use	7.1	3.3		
• Blood transfusions	0	2.2		

CD4: number of CD4+ T-cells, %: percentage of patients, IV drug use: intravenous drug use